| pubmed-article:17726701 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17726701 | lifeskim:mentions | umls-concept:C0010674 | lld:lifeskim |
| pubmed-article:17726701 | lifeskim:mentions | umls-concept:C0014508 | lld:lifeskim |
| pubmed-article:17726701 | lifeskim:mentions | umls-concept:C1511726 | lld:lifeskim |
| pubmed-article:17726701 | lifeskim:mentions | umls-concept:C1135662 | lld:lifeskim |
| pubmed-article:17726701 | lifeskim:mentions | umls-concept:C0034975 | lld:lifeskim |
| pubmed-article:17726701 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:17726701 | pubmed:dateCreated | 2007-9-4 | lld:pubmed |
| pubmed-article:17726701 | pubmed:abstractText | After closure of the Epidemiologic Registry of Cystic Fibrosis (ERCF), a comprehensive safety analysis of dornase alfa was performed. A planned subanalysis focused on children under 5 years old. Reported serious adverse events (SAEs) were assigned a preferred term and ascribed to a specific organ system. Possible serious adverse reactions to dornase alfa (SADRs) were identified by reporting clinics. Twenty-eight of 15,865 SAEs (0.18%), occurring in 26 of 6,829 patients ever treated with dornase alfa (0.38%), and no deaths were reported as possible SADRs: most were typical complications of cystic fibrosis (CF). There was no evidence of any unrecognized risk of treatment. During 24,586 patient-years of follow-up (FU) of ever-treated patients, SAEs (mostly typical respiratory complications of CF) were more frequent on-treatment (0.4999/patient-year; 95% CI 0.4921-0.5076) than off-treatment (0.3889; 0.3787-0.3992). This was likely caused by within-patient prescription bias. During 655 patient-years of FU in 328 ever-treated patients under 5 years old, SAEs (mostly pulmonary exacerbations of CF) were slightly less frequent during treatment: 0.2911 (0.2367-0.3455) versus 0.3563 (0.3086-0.4040; ns). Results confirm the safety of dornase alfa in CF patients of all ages. Children under 5 years old tolerate dornase alfa at least as well as older patients. | lld:pubmed |
| pubmed-article:17726701 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17726701 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17726701 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17726701 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17726701 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17726701 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17726701 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17726701 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17726701 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:17726701 | pubmed:issn | 8755-6863 | lld:pubmed |
| pubmed-article:17726701 | pubmed:author | pubmed-author:HodsonM EME | lld:pubmed |
| pubmed-article:17726701 | pubmed:author | pubmed-author:ChowdhurySS | lld:pubmed |
| pubmed-article:17726701 | pubmed:author | pubmed-author:McKenzieS GSG | lld:pubmed |
| pubmed-article:17726701 | pubmed:author | pubmed-author:StrandvikBB | lld:pubmed |
| pubmed-article:17726701 | pubmed:author | pubmed-author:Investigators... | lld:pubmed |
| pubmed-article:17726701 | pubmed:copyrightInfo | (c) 2007 Wiley-Liss, Inc. | lld:pubmed |
| pubmed-article:17726701 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17726701 | pubmed:volume | 42 | lld:pubmed |
| pubmed-article:17726701 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17726701 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17726701 | pubmed:pagination | 928-37 | lld:pubmed |
| pubmed-article:17726701 | pubmed:meshHeading | pubmed-meshheading:17726701... | lld:pubmed |
| pubmed-article:17726701 | pubmed:meshHeading | pubmed-meshheading:17726701... | lld:pubmed |
| pubmed-article:17726701 | pubmed:meshHeading | pubmed-meshheading:17726701... | lld:pubmed |
| pubmed-article:17726701 | pubmed:meshHeading | pubmed-meshheading:17726701... | lld:pubmed |
| pubmed-article:17726701 | pubmed:meshHeading | pubmed-meshheading:17726701... | lld:pubmed |
| pubmed-article:17726701 | pubmed:meshHeading | pubmed-meshheading:17726701... | lld:pubmed |
| pubmed-article:17726701 | pubmed:meshHeading | pubmed-meshheading:17726701... | lld:pubmed |
| pubmed-article:17726701 | pubmed:meshHeading | pubmed-meshheading:17726701... | lld:pubmed |
| pubmed-article:17726701 | pubmed:meshHeading | pubmed-meshheading:17726701... | lld:pubmed |
| pubmed-article:17726701 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17726701 | pubmed:articleTitle | Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. | lld:pubmed |
| pubmed-article:17726701 | pubmed:affiliation | F. Hoffmann-La Roche Ltd, Basel, Switzerland. | lld:pubmed |
| pubmed-article:17726701 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17726701 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17726701 | lld:pubmed |
